Listen Now
Topics Covered
- The Treatment of Triple Negative Breast Cancer, in the Context of COVID-19
- Why Clinical Trials Are Important as a Treatment Option for Triple Negative Breast Cancer
- What Happens in a Clinical Trial
- Stages of Clinical Trials
- New Research in the Treatment of Triple Negative Breast Cancer (TNBC)
- Investigational New Drugs in Clinical Trials
- The Meaning of Informed Consent
- Benefits & Risks of Participation
- How & Where Clinical Trials are Conducted
- How to Participate in Clinical Trials
- Specific Questions to Ask Your Health Care Team about Clinical Trials
- Guidelines to Prepare for Telehealth/Telemedicine Appointments, including Technology, Prepared List of Questions & Discussion of OpenNotes
- Accessing Resources for Clinical Trials
- Questions for Our Panel of Experts
Our Panel of Experts

Generosa Grana, MD, FACP
Medical Director, MD Anderson Cancer Center at Cooper, Division Head, Hematology & Medical Oncology, The Cooper Health System, Professor of Medicine, Cooper Medical School at Rowan University

Minetta C. Liu, MD
Professor and Research Chair, Division of Medical Oncology, Department of Oncology, Consultant, Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Medical Director, Office of Specialty Collaborations and Contracts, Co-Leader, Genomics in Action Strategic Priority, Center for Individualized Medicine, Mayo Clinic

Jennifer M. Matro, MD
Associate Clinical Professor of Medicine, Division of Hematology/Oncology, University of California San Diego Health

Hayley Dinerman, JD
Co-Founder and Executive Director, Triple Negative Breast Cancer Foundation®

Carolyn Messner, DSW, BCD, FAPOS, FAOSW
Director of Education and Training, CancerCare
Brochure
You can download the brochure for this workshop
Workshop Date
This workshop was originally recorded on November 03, 2021.